1. Introduction
===============

Vitamin D plays an essential role in the regulation of metabolism, calcium and phosphorus absorption of bone health. However, the effects of vitamin D are not limited to mineral homeostasis and skeletal health maintenance. The presence of vitamin D receptors (VDR) in other tissue and organs suggest that vitamin D physiology extends well above and beyond bone homeostasis \[[@B1-nutrients-05-03605]\]. Additionally, the enzyme responsible for the conversion of 25\[OH\] D to its biologically active form \[Vitamin D (1,25\[OH\]~2~ D)\] has been identified in other tissues aside from kidneys \[[@B2-nutrients-05-03605],[@B3-nutrients-05-03605]\], and that extra renal synthesis of 1,23\[OH\]~2~D may be equally important in regulating cell growth and differentiation via paracrine or autocrine regulatory mechanisms \[[@B4-nutrients-05-03605]\].

The mechanism of action of vitamin D~3~ through its hormonal form, dihydroxyvitaminD~3~, involves a nuclear VDR that regulates the transcription of several target genes in a variety of vitamin D target cells that are primarily involved in the calcium homeostasis of cell differentiation \[[@B5-nutrients-05-03605]\]. Hypervitaminosis D occurs when pharmacologic doses of vitamin D are consumed for prolonged periods of time or from a single megadose translating to a large increase in circulating 25\[OH\]D concentrations \[[@B6-nutrients-05-03605]\].

2. Vitamin D Metabolism
=======================

Vitamin D has two distinct forms: vitamins D~2~ and D~3~. Vitamin D~2~ is a 28-carbon molecule derived from ergosterol (a component of fungal cell membranes), while vitamin D~3~ is a 27-carbon derived from cholesterol \[[@B7-nutrients-05-03605]\]. UV-B irradiation of skin triggers photolysis of 7-dehydrocholesterol (pro-vitamin D~3~) to pre-vitamin D~3~, which is rapidly converted to vitamin D~3~ by the skin's temperature. Vitamin D (D~2~ and D~3~) from the skin and diet undergo two sequential hydroxylations: first in the liver (25\[OH\]D) and then in the kidney, leading to its biologically active form 1,25-dihydroxyvitamin D (1,25\[OH\]~2~D) \[[@B8-nutrients-05-03605]\]. [Table 1](#nutrients-05-03605-t001){ref-type="table"} shows the nomenclature for vitamin D precursors and metabolites.
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###### 

Nomenclature of vitamin D precursors and metabolites.

  Common Name            Clinical Name            Abbreviation     Comments
  ---------------------- ------------------------ ---------------- ----------------------------------------------------------------------------------
  7-Dehydrocholesterol   Pro-vitamin D~3~         7DHC             Lipid in cell membranes
  Cholecalciferol        Pre-vitamin D~3~                          Photosynthesized in skin or diet
  Ergocalciferol         Pre-vitamin D~2~                          Obtained from diet. Equivalent to vitamin D~3~ as precursor for active vitamin D
  Calcidiol              25-Hydroxyvitamin D      25\[OH\]D        Best reflects vitamin D status
  Calcitriol             1,25-Dihydroxvitamin D   1,25\[OH\]D~2~   Active form of vitamin D, tightly regulated

The 1,25 \[OH\]~2~D ligand binds with high affinity to vitamin D receptors (VDRs), which then increases intestinal absorption of both calcium and phosphorus. In addition, vitamin D is actively involved in bone formation, resorption, mineralization, and in maintenance of neuromuscular function. Circulating 1,25\[OH\]~2~D inhibits serum parathyroid hormone (PTH) levels by negative feedback mechanism and by increased serum calcium levels. It also regulates bone metabolism through activation of the VDRs found in osteoblasts, releasing biochemical signals and leading to the formation of mature osteoclasts \[[@B9-nutrients-05-03605]\].

In a low vitamin D state, the small intestine can absorb approximately 10%--15% of dietary calcium. When adequate however, intestinal absorption of dietary calcium rises to approximately 30%--40% \[[@B9-nutrients-05-03605],[@B10-nutrients-05-03605]\]. Hence, low vitamin D levels (25\[OH\]D) may lead to insufficient calcium absorption, and this has clinical implications not only for bone health but also for most metabolic functions. The increase in PTH restores calcium homeostasis by increasing tubular reabsorption of calcium in the kidney, increasing bone calcium mobilization and enhancing 1,25\[OH\]~2~D production \[[@B10-nutrients-05-03605]\].

3. Optimum 25\[OH\]D Levels
===========================

The vitamin D level needed to optimize intestinal calcium absorption (34 ng/mL) is lower than the level needed for neuromuscular performance (38 ng/mL) \[[@B11-nutrients-05-03605],[@B12-nutrients-05-03605]\]. Experts however believe that the lower limit of adequate 25\[OH\]D levels should be 30 ng/mL \[[@B13-nutrients-05-03605]\]. Still others recommend a lower limit of 40 ng/mL, since impaired calcium metabolism due to low serum 25\[OH\]D levels may trigger secondary hyperparathyroidism, increased bone turnover and progressive bone loss \[[@B14-nutrients-05-03605],[@B15-nutrients-05-03605]\].

The proposed 25\[OH\]D cut-off for optimum skeletal health is the level that reduces PTH to a minimum and increases calcium absorption to its maximum \[[@B11-nutrients-05-03605],[@B16-nutrients-05-03605]\]. Several studies have shown that PTH levels plateau at a minimum steady-state level as serum 25\[OH\]D levels approach and rise above approximately 30 ng/mL (75 nmol/L) \[[@B16-nutrients-05-03605],[@B17-nutrients-05-03605],[@B18-nutrients-05-03605]\]. The established consensus of several vitamin D cut-offs is presented in [Table 2](#nutrients-05-03605-t002){ref-type="table"} \[[@B18-nutrients-05-03605],[@B19-nutrients-05-03605],[@B20-nutrients-05-03605]\]. It is noteworthy, however, that there is a continued debate and exchange of knowledge with respect to the optimum cut-off for 25(OH)D.
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###### 

Diagnostic Cut-Offs of levels of serum 25\[OH\]D.

  25\[OH\] Level (ng/mL)   25\[OH\]D Level (nmoL/L)   Laboratory Diagnosis
  ------------------------ -------------------------- ---------------------------
  \<20                     \<50                       Deficiency
  20--32                   50--80                     Insufficiency
  54--90                   135--225                   Normal in sunny countries
  \>100                    \>250                      Excess
  \>150                    \>325                      Intoxication

4. Measurements of 25\[OH\]D *versus* 1,25\[OH\]~2~D~3~
=======================================================

The clinical advantages of choosing 25\[OH\]D instead of calcitriol as a marker for vitamin D status has been listed by Rajasree *et al*. \[[@B21-nutrients-05-03605]\]. First, 25\[OH\]D has the highest concentration of all vitamin D metabolites. Second, its levels remain stable for almost two weeks. Lastly, vitamin D toxicity is thought to be a function of 25\[OH\]D instead of calcitriol. It has been observed that serum 25\[OH\]D is the best indicator of vitamin D status among individuals without kidney disease \[[@B22-nutrients-05-03605]\]. Furthermore, 25\[OH\]D in large amounts can replace calcitriol to stimulate bone calcium metabolism \[[@B23-nutrients-05-03605]\]. Although nephrectomy abolishes a response to physiological dose of 25\[OH\]D, a large dose (1000 fold) of 25\[OH\]D can stimulate intestinal calcium absorption and bone calcium metabolism in nephrectomized rats \[[@B24-nutrients-05-03605]\]. Hughes *et al.*, studied vitamin D intoxication in two human patients with normal kidney function and showed that both patients had 16-fold above normal concentrations of plasma 25\[OH\]D levels (500--600 ng/mL), while 1,25\[OH\]D~2~D~3~ plasma concentrations were only modestly elevated (40--56 pg/mL) \[[@B25-nutrients-05-03605]\]. Differences in calcidiol *versus* calcitriol are presented in [Table 3](#nutrients-05-03605-t003){ref-type="table"}.
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###### 

Calcidiol *versus* Calcitriol.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Metabolite function   25\[OH\]D                                                           1,25\[OH\]~2~D~3~
  --------------------- ------------------------------------------------------------------- --------------------------------------------------
  Nutritional Status    Best indicator                                                      Does not indicate nutritional status

  Half life             \>15 days                                                           \<15 h

  Stability in serum    Stable                                                              Unstable

  Hypovitaminosis D     Indicative (low)                                                    Non-indicative\
                                                                                            (normal to elevated)

  Hypervitaminosis D    Indicative (elevated)                                               Non-indicative (low to normal or mild elevated)

  Calcium regulation    Possible under\                                                     Tight under\
                        non-physiological conditions                                        physiological conditions

  PTH regulation        Depends on vitamin D status                                         Tight

  DBP binding           High affinity (releases the free metabolite once DBP is saturated   Low affinity to exert the physiological function

  VDR binding           Strongest among metabolite other than calcitriol                    High affinity to elicit the biological function
  --------------------------------------------------------------------------------------------------------------------------------------------

**Note**: VDR: vitamin D receptor; DBP: vitamin D binding protein; PTH: parathyroid hormone.

5. Supplementation of Vitamin D~2~ *versus* Vitamin D~3~
========================================================

Multiple preparations of vitamin D and its metabolites are commercially available for supplement use. The two most common supplements are ergocalciferol (vitamin D~2~) and cholecalciferol (vitamin D~3~). Some studies \[[@B26-nutrients-05-03605],[@B27-nutrients-05-03605]\], but not all \[[@B28-nutrients-05-03605]\], suggest that vitamin D~3~ increases serum 25\[OH\]D more efficiently than vitamin D~2~. A large, single dose of vitamin D~2~ does not last longer than a large dose of D~3~. In a study conducted by Armas *et al*., \[[@B27-nutrients-05-03605]\], subjects were given one dose of 50,000 IU of either vitamin D~2~ or vitamin D~3~. Vitamin D~2~ was absorbed just as well as vitamin D~3~, yet blood levels of 25\[OH\]D started dropping rapidly after 3 days among subjects given vitamin D~2~ whereas those on vitamin D~3~ sustained high levels for two weeks before dropping gradually.

A daily dose of 4000 IU of vitamin D~3~ for two weeks was observed to be 1.7 times more effective in raising 25\[OH\]D levels than 4000 IU of vitamin D~2~ \[[@B26-nutrients-05-03605]\]. On the other hand, Holick *et al.* found that a daily dose of 1000 IU of vitamin D~2~ over 11 weeks duration increased 25\[OH\]D levels from 42 to 67 nmoL/L (16.9 to 26.8 ng/mL) \[[@B28-nutrients-05-03605]\]. Consequently, vitamin D~3~ levels also increased from 49 to 72 nmoL/L (19.6 to 28.9 ng/mL). It took 6 weeks for 25\[OH\]D levels to plateau on that regimen. In another study, Glendenning *et al.* compared 1000 IU of D~2~ *versus* D~3~ in patients who had vitamin D insufficiency with subsequent hip fractures. After three months, those who were supplemented with D~3~ had a 31%--52% greater increase in 25\[OH\]D levels than those supplemented with D~2~. However, parathyroid hormone levels did not differ between groups \[[@B29-nutrients-05-03605]\].

In children, Gordon *et al.*, assigned 40 infants and toddlers with vitamin D deficiency to one of three regimens (2000 IU oral vitamin D~2~ daily, 50,000 IU vitamin D~2~ weekly or 2000 IU vitamin D~3~ daily) for 6 weeks. At the end of the trial, 25\[OH\]D levels increased from 42.5 to 90 nmoL/L and there were no significant differences between treatment groups \[[@B30-nutrients-05-03605]\].

In terms of bioavailability, Biancuzzo *et al.*, tested changes in 25\[OH\]D status from a daily dose of 1000 IU of vitamin D~2~ or D~3~ from either calcium-fortified orange juice with vitamin D or supplement capsules for 11 weeks. The average 25\[OH\]D levels of all groups (D~2~ from orange juice, D~2~ from capsules, D~3~ from orange juice, D~3~ from capsules) went up to about 25 nmoL/L with no significant differences between groups \[[@B31-nutrients-05-03605]\].

Treatment for most studies found D~2~ to be less effective than D~3~, whereas in studies finding them equally effective, the treatment was daily amounts between 400 and 2000 IU \[[@B32-nutrients-05-03605]\]. Houghton and Vieth indicated that vitamin D~3~ is the most potent form of vitamin D in all primate species, including humans, owing to the diminished binding of vitamin D~2~ metabolites to DBP in plasma \[[@B33-nutrients-05-03605]\]. They also confirmed the finding of Hollick \[[@B34-nutrients-05-03605]\], which indicated that the difference in binding capacity is potentially explained by the presence of a methyl group at carbon-24 position on the D~2~ molecule. The different hydroxylation sites of two forms of vitamin D leads to the production of unique biologically active metabolites. Based on this, the 24-hydroxylation after the 25-hydroxylation results in the formation of 1,24,25\[OH\]~3~D~2~ and the deactivation of vitamin D~2~ molecule. On the other hand, the vitamin D~3~ metabolite 1,24,25\[OH\]~3~D~3~ must undergo an additional side chain oxidation to be biologically deactivated \[[@B35-nutrients-05-03605]\]. Interestingly, 1,24,25\[OH\]~3~D~3~ has the ability to bind VDR with \~40% capacity higher than with 1,25\[OH\]~2~D~3~ \[[@B36-nutrients-05-03605]\].

6. Candidates for Calcidiol (25-OHD) Measurements
=================================================

The best indicator of vitamin D status is 25-OHD because it reflects cutaneous and dietary intake, not to mention it is the major circulating form of vitamin D \[[@B37-nutrients-05-03605]\]. While there are many established causes of vitamin D deficiency, as listed in [Table 4](#nutrients-05-03605-t004){ref-type="table"}, screening for the general population warrants further investigation. The United States Preventive Services Task Force (USPSTF) did not comment for or against routine screening for vitamin D deficiency. One approach is to consider serum testing in patients at high risk for vitamin D deficiency, and treating without testing those at a lower risk \[[@B38-nutrients-05-03605]\]. Just recently, a statement from Osteoporosis Canada suggested that based on clinical suspicion for vitamin D insufficiency and its complications the clinical approach can take into account three settings ([Table 5](#nutrients-05-03605-t005){ref-type="table"}).
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###### 

Major causes of vitamin D deficiency \[[@B13-nutrients-05-03605]\].

  Causes                                           Example
  ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------
  Reduced skin synthesis                           Sunscreen, skin pigment, season/time of day, aging
  Decreased absorption                             Cystic fibrosis, celiac disease, Crohn's disease, gastric bypass, medications that reduce cholesterol absorption
  Increased sequestration                          Obesity (BMI \> 30)
  Increased catabolism                             Anti-convulsant, glucocorticoid
  Breastfeeding                                    Exclusively without vitamin D supplementation
  Decreased synthesis of 25-hydroxyvitamin D       Hepatic failure
  Increased urinary loss of 25-hydroxyvitmain D    Nephrotic proteinuria
  Decreased synthesis of 1,25-dihydroxyvitmain D   Chronic renal failure
  Inherited disorders                              Vitamin D resistance
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###### 

Approach to vitamin D correction \[[@B39-nutrients-05-03605]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk Category                                                                                 Action                                                                                                                                                                     Level of Evidence
  --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  Low:\                                                                                         400--1000 IU\                                                                                                                                                              Level 3\
  Adult \< 50 years\                                                                            No calcidiol measurement required                                                                                                                                          Evidence grade D
  Without comorbid conditions affecting vitamin D absorption or action                                                                                                                                                                                                     

  Moderate:\                                                                                    800--2000 IU\                                                                                                                                                              Level 2\
  Adult \> 50 years\                                                                            Calcidiol measurement in initial assessment but if therapy for osteoporosis is prescribed, calcidiol should be measured after three to four months, of an adequate dose.   Evidence grade B\
  With or without osteoporosis\                                                                                                                                                                                                                                            Level 3\
  but without comorbid conditions that affect vitamin D absorption or action                                                                                                                                                                                               Evidence grade D

  High:\                                                                                        Calcidiol should be measured and supplementation based on the measured value.                                                                                              Grade B\
  Co-morbid conditions that affect vitamin D absorption or action and/or recurrent fractures\                                                                                                                                                                              Recommendation
  or bone loss despite\                                                                                                                                                                                                                                                    
  osteoporosis treatment                                                                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

7. Vitamin D Correction
=======================

In patients with normal absorptive capacity, for every 40 IU/day (1 µg/day) of vitamin D~3~, serum 25(OH)D concentrations increase by approximately 0.3 to 0.4 ng/mL (0.7 to 1.0 nmol/L) \[[@B40-nutrients-05-03605]\]. Largest increments are seen in patients with the lowest starting 25(OH)D level, but subsequently declines as 25(OH)D concentration reaches 40 ng/mL (100 nmol/L) \[[@B41-nutrients-05-03605]\]. Nutritional deficiency (25OHD \< 50 nmol/L) requires initial treatment with 50,000 units of vitamin D~2~ or vitamin D~3~ orally once per week for 6--8 weeks, and then 800 to 1000 IU of vitamin D~3~ orally thereafter \[[@B42-nutrients-05-03605]\]. Intramuscular cholecalciferol (300,000 IU) in one or two doses per year is also an option for increasing serum 25 OHD level \[[@B43-nutrients-05-03605]\].

Nutritional insufficiency (25 OHD 50--75 nmol/L) requires treatment with 800 to 1000 IU of vitamin D~3~ daily. This intake will bring the average adult's vitamin D status to 7 nmol/L higher over a three-month period. Still, many individuals might need higher doses. In malabsorptive states, oral dosing and duration of treatment is dependent on the individual patient's on vitamin D absorptive capacity. High doses of vitamin D (10,000 to 50,000 IU daily) may be necessary for patients who had gastrectomy or malabsorption history. Patients who remain deficient or insufficient on such doses need to be treated with hydroxylated vitamin D metabolites, since they are more readily absorbed than with ordinary sun or sun camp exposure. All patients should maintain a daily calcium intake of at least 1000 mg (for ages 31 to 50 years) to 1200 mg (for ages 51 and older) per day \[[@B44-nutrients-05-03605]\].

8. Vitamin D Toxicity
=====================

Vitamin D as a fat-soluble vitamin raised concerns about toxicity from excessive supplementation. Widespread vitamin D fortification of foods and drinks from the 1930s to 1950s in the United States and Europe led to reported cases of toxicity \[[@B45-nutrients-05-03605]\]. Hypercalcemia is responsible for producing most of the symptoms of vitamin D toxicity. Early symptoms of vitamin D toxicity include gastrointestinal disorders like anorexia, diarrhea, constipation, nausea, and vomiting. Bone pain, drowsiness, continuous headaches, irregular heartbeat, loss of appetite, muscle and joint pain are other symptoms that are likely to appear within a few days or weeks; frequent urination, especially at night, excessive thirst, weakness, nervousness and itching; kidney stones \[[@B46-nutrients-05-03605]\].

There are three major hypotheses for vitamin D toxicity \[[@B47-nutrients-05-03605]\]: (i)**Raised plasma 1,25\[OH\]D concentrations lead to increased intracellular 1,24\[OH\]D concentrations.** This hypothesis is not widely supported as many studies revealed that vitamin D toxicity is associated with normal or marginally elevated 1,25\[OH\]D \[[@B23-nutrients-05-03605]\]. It was only Mawer *et al.* who reported elevated 1,25\[OH\]D with vitamin D toxicity \[[@B48-nutrients-05-03605]\].(ii)**Vitamin D intake raises plasma 25\[OH\]D levels to concentrations that exceed DBP binding capacity, and free 25\[OH\]D has direct effects on gene expression once it enters target cells.** High dietary vitamin D intake alone increases plasma 25\[OH\]D. The low affinity of 1,25\[OH\]D for the transport protein DBP and its high affinity for VDR dominate normal physiology. This makes it the only ligand with access to the transcriptional signal transduction machinery. However, in vitamin D intoxication, overloading by various vitamin D metabolites significantly compromises the capacity of the DBP by allowing other metabolites to enter the cell nucleus. Of all the inactive metabolites, 25\[OH\]D has the strongest affinity for the VDR, and thus at sufficiently high concentrations, could stimulate transcription \[[@B47-nutrients-05-03605]\].(iii)**Vitamin D intake raises the concentrations of many vitamin D metabolites**, including vitamin D itself and 25\[OH\]D, and these concentrations exceed the DBP binding capacity and release of "free" 1,25\[OH\]D which enters target cells \[[@B47-nutrients-05-03605]\].

The amount of UVB radiation required for vitamin D sufficiency can be calculated from the amount of vitamin D produced from one minimal erythemal dose (MED), or 10,000--25,000 IU of oral vitamin D \[[@B9-nutrients-05-03605]\].The MED can be defined as the amount of time needed to cause skin to turn pink. The length of time varies with geographical location, skin pigmentation, percent of body fat, and age. Excessive exposure to sunlight will not cause vitamin D intoxication because sunlight degrades any excess vitamin D \[[@B48-nutrients-05-03605]\].

The highest recorded individual serum 25\[OH\]D concentration obtained from sunshine was from a farmer in Puerto Rico with a level of 225 nmol/L \[[@B49-nutrients-05-03605]\]. On the other hand, the highest recorded individual 25\[OH\]D achieved from artificial ultraviolet light treatment sessions was 275 nmol/L \[[@B50-nutrients-05-03605]\]. Vieth reported that vitamin D toxicity probably begins to occur after chronic consumption of approximately 40,000 IU/day (100 of the 400 IU capsules) \[[@B6-nutrients-05-03605]\]. Reports in which pharmacologic doses of vitamin D were given for a prolonged time, the indications why it was given and in which the final serum 25\[OH\]D concentrations are provided and summarized in [Table 6](#nutrients-05-03605-t006){ref-type="table"}.

9. Hypersensitivity to Vitamin D
================================

Vitamin D hypersensitivity syndromes are often mistaken for vitamin D toxicity. The most common is primary hyperparathyroidism. Granulomatous diseases, such as sarcoidosis, granulomatous TB and some cancers also cause vitamin D hypersensitivity, as the granuloma or the tumor may make excessive amounts of calcitriol, thus raising serum calcium levels \[[@B6-nutrients-05-03605]\].
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###### 

Studies reporting elevated vitamin D status and associated diseases.

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Reference, year, and daily dosage (µg)                               Duration       Final 25\[OH\]D concentration (nmoL/L)   Indication
  -------------------------------------------------------------------- -------------- ---------------------------------------- --------------------
  Mason *et al.*, \[[@B51-nutrients-05-03605]\], 1980 1250             \>52 weeks     717                                      Hypoparathyroidism

  Haddock *et al.*, \[[@B49-nutrients-05-03605]\], 1982 1875           \>100 weeks    1707.5                                   Hypoparathyroidism

  Gertner and Domenech \[[@B52-nutrients-05-03605]\], 1977 500--2000   12--52 weeks   442--1022                                Various

  Counts *et al.*, \[[@B53-nutrients-05-03605]\],\                     12 weeks       1550                                     Anephric
  1975 2500                                                                                                                    

  Hughes *et al.*, \[[@B25-nutrients-05-03605]\], 1976\                \>52 weeks     1000--1600                               Not stated
  2500--6250 *n* = 3                                                                                                           

  Streck *et al.*, \[[@B54-nutrients-05-03605]\], 1979 2500            3.8 years      707.5                                    Hypoparathyroidism

  Davies and Adams \[[@B55-nutrients-05-03605]\], 1978                                                                         

  3750                                                                 364 weeks      1125                                     Paget disease

  2500                                                                 520 weeks      1000                                     Thyroidectomy

  Mawer *et al.*, \[[@B48-nutrients-05-03605]\], 1985                                                                          Hypoparathyroidism

  1875                                                                 520 weeks      568                                      Hypophosphatemic

  5000                                                                 520 weeks      1720                                     rickets

  2500                                                                 520 weeks      995                                      Carpal tunnel

  1250                                                                 1248 weeks     632                                      syndrome

  4285                                                                 26 weeks       908                                      Celiac disease

  2500                                                                 520 weeks      856                                      Chilblain

  2500                                                                 312 weeks      778                                      Thyroidectomy

  1250                                                                 1040 weeks     903                                      Arthritis

                                                                                                                               Hypoparathyroidism

  Allen and Skah \[[@B56-nutrients-05-03605]\], 1992                                                                           Hypoparathyroidism

  1875                                                                 19 years       267                                      

  Rizzoli *et al.*, \[[@B57-nutrients-05-03605]\], 1994                                                                        

  15,000                                                               96 weeks       221                                      

  7500                                                                 3 weeks        801                                      Osteoporosis

  7500                                                                 74 weeks       1692                                     Osteoporosis

  1075                                                                 12 weeks       374                                      Hypoparathyroidism

  7500                                                                 4 weeks        650                                      Osteoporosis

  7500                                                                 4 weeks        621                                      Osteoporosis

  250                                                                  390 weeks      608                                      Osteomalacia

  Pettifor *et al.*, \[[@B58-nutrients-05-03605]\] 1995                                                                        Not stated

  50,000 (*n* = 11)                                                    10 days        847--1652                                

  Jacobus *et al.*, \[[@B59-nutrients-05-03605]\] 1992                                                                         Not stated

  725--4364 (*n* = 8)                                                  6 years        "mean" 731                               
  -------------------------------------------------------------------------------------------------------------------------------------------------

10. Conclusions
===============

The present review discussed current knowledge on vitamin D physiology, its clinical relevance and evidence-based treatment options on vitamin D status correction. Caution should still be practiced by clinicians in providing vitamin D supplementation among vitamin D deficient populations, with proper monitoring using approved and certified methods. Indications for vitamin D supplementation outside the conventional calcium homeostasis should also be considered to maximize extra-skeletal benefits of vitamin D correction.
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